Detalhe da pesquisa
1.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482193
2.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(7): 919-930, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690073
3.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 277-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33357510
4.
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
; 127(14): 2432-2441, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740262
5.
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecol Oncol
; 161(2): 502-507, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33612336
6.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet
; 394(10214): 2084-2095, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791688
7.
European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.
Int J Gynecol Cancer
; 30(4): 428-433, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32046979
8.
Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Int J Gynecol Cancer
; 30(7): 1026-1033, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32321768
9.
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Gynecol Oncol
; 154(2): 441-448, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118141
10.
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
Gynecol Oncol
; 161(1): 328-329, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33551198
11.
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448].
Gynecol Oncol
; 157(2): 558-559, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32087992
12.
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development.
Int J Gynecol Cancer
; 30(6): 730-734, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32404377
13.
Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Int J Gynecol Cancer
; 24(9 Suppl 3): S78-82, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341585
14.
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.
Int J Gynecol Cancer
; 24(9 Suppl 3): S42-7, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341579
15.
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Int J Gynecol Cancer
; 24(9 Suppl 3): S55-60, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341582
16.
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.
Int J Gynecol Cancer
; 24(9 Suppl 3): S83-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341586
17.
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.
Int J Gynecol Cancer
; 24(9 Suppl 3): S9-13, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341587
18.
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.
Int J Gynecol Cancer
; 24(9 Suppl 3): S90-5, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341588
19.
Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.
Int J Gynecol Cancer
; 24(9 Suppl 3): S26-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25126954
20.
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Int J Gynecol Cancer
; 24(9 Suppl 3): S20-5, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25341576